UPDATE: Goldman Sachs Raises Medicis Pharmaceuticals' PT

According to a research report published earlier today, Goldman Sachs has increased Medicis Pharmaceuticals'

PT from $38 to $41. Goldman Sachs said in the report, “Guidance for 2012, near-term ASP guidance for Solodyn and Ziana, and greater color on the Zyclara strategy left us feeling more comfortable with both the 2012 outlook and the company's longer-term growth strategy. Going forward, the key areas of focus will be understanding the Rx Assist initiative and greater clarity on the growing pipeline. We maintain our Neutral rating, but we have increased our price target.” Medicis Pharmaceuticals is currently trading at $35.60.